<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-4142</journal-id>
<journal-title><![CDATA[Revista Costarricense de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. costarric. cardiol]]></abbrev-journal-title>
<issn>1409-4142</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-41422002000300006</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Avances en el tratamiento de la hipertensión arterial con antagonistas de los receptores de angiotensina]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[Vivencio]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tomás]]></surname>
<given-names><![CDATA[Juan Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[Luis Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Hospital Ramón y Cajal  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Hospital 12 de Octubre  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2002</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2002</year>
</pub-date>
<volume>4</volume>
<numero>3</numero>
<fpage>29</fpage>
<lpage>37</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-41422002000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-41422002000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-41422002000300006&amp;lng=en&amp;nrm=iso"></self-uri></article-meta>
</front><body><![CDATA[  <b><font face="Arial,Helvetica"><font size="-1">Revisi&oacute;n</font></font></b>     <center><b><font face="Arial,Helvetica">Avances en el tratamiento de la hipertensi&oacute;n arterial con antagonistas de los</font></b></center>     <center><b><font face="Arial,Helvetica">receptores de angiotensina</font></b></center>     <center>&nbsp;</center>     <center>&nbsp;</center>     <center><font face="Arial,Helvetica"><font size="-1">Dr. Vivencio Barrios<a name="*a"></a><a href="#*">*</a>&nbsp;&nbsp;&nbsp; Dr. Juan Pablo Tom&aacute;s<a href="#*">*</a>&nbsp;&nbsp;&nbsp; Dr. Luis Miguel Ruilope<a href="#*">**</a></font></font></center> &nbsp;     <br> &nbsp;     <br> <b><font face="Arial,Helvetica"><font size="-1">Introducci&oacute;n</font></font></b>     <p><i><font face="Arial,Helvetica"><font size="-1">"Como la obesidad y la diabetes, la hipertensi&oacute;n esencial es una enfermedad de la civilizaci&oacute;n del hombre, que resulta de la colisi&oacute;n de un moderno estilo de vida con genes paleol&iacute;ticos. "</font></font></i> </p>     <p><font face="Arial,Helvetica"><font size="-1">Alan B. Weder.</font></font>     ]]></body>
<body><![CDATA[<br> &nbsp; </p>     <p><font face="Arial,Helvetica"><font size="-1">La enfermedad cardiovascular constituye el mayor problema de salud en cifras absolutas de morbi-mortalidad en los pa&iacute;ses occidentales, principalmente por encima de los 60 a&ntilde;os, y la hipertensi&oacute;n arterial (HTA) constituye el principal factor de riesgo asociado al desarrollo de las enfermedades cardiovasculares. Un estudio realizado en nuestro pa&iacute;s demuestra que entre los individuos de 35 a 64 a&ntilde;os de edad, el 42% de las muertes por enfermedad coronaria, el 46.4% de las muertes por enfermedad cerebrovascular y el 25% de las muertes de cualquier causa est&aacute;n relacionadas con la presencia de HTA (<a href="#1">1</a>). En otro reciente estudio espa&ntilde;ol que incluy&oacute; m&aacute;s de 32.000 pacientes atendidos en consultas de atenci&oacute;n primaria o de cardiolog&iacute;a, entre los pacientes con cardiopat&iacute;a, la HTA estaba presente en un porcentaje muy alto de casos, en el 71% de los pacientes con insuficiencia card&iacute;aca, en el 66% de los pacientes con cardiopat&iacute;a isqu&eacute;mica y en el 66% de los casos de fibrilaci&oacute;n auricular (<a href="#2">2</a>). La prevalencia de HTA en Espa&ntilde;a cl&aacute;sicamente se estimaba en un 20%-30% en la poblaci&oacute;n de edad media, alcanzando cifras del orden del 60% en mayores de 65 a&ntilde;os (<a href="#3">3</a>). Pero estas cifras son considerando HTA con presi&oacute;n arterial (PA) &gt;160/95; si se considera HTA como actualmente, con PA &gt;140/90, las cifras son a&uacute;n superiores, alcanzando un 45.1% (<a href="#1">1</a>). Pero adem&aacute;s teniendo en cuenta que la poblaci&oacute;n tiende a envejecer y que est&aacute; aumentando la cifra de hipertensos entre los adolescentes, no es dif&iacute;cil deducir que la incidencia de HTA aumentar&aacute; en las d&eacute;cadas futuras con el incremento de morbi-mortalidad por complicaciones cardiovasculares.</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">Al haberse comprobado una relaci&oacute;n lineal entre los valores de PA sist&oacute;lica y diast&oacute;lica con la morbi-mortalidad cardiovascular, el objetivo principal del tratamiento de la HTA es reducir la PA hasta los niveles recomendados por las diferentes gu&iacute;as publicadas al respecto (<a href="#4">4</a>,<a href="#5">5</a>). El desaf&iacute;o del tratamiento farmacol&oacute;gico es sumar los beneficios obtenidos con la Deducci&oacute;n sostenida de la PA a la protecci&oacute;n cardiovascular que podr&iacute;an conferir ciertos f&aacute;rmacos, a trav&eacute;s de efectos que ser&iacute;an independientes del descenso de PA(6).</font></font>     <br> &nbsp; </p>     <p><b><font face="Arial,Helvetica"><font size="-1">Importancia del Sistema Renina-Angiotensina-Aldosterona en Hipertensi&oacute;n</font></font></b> </p>     <p><font face="Arial,Helvetica"><font size="-1">El sistema renina-angiotensina-aldosterona (SRAA) se ha considerado un sistema encargado de la regulaci&oacute;n de la PA y del volumen extracelular. Posteriormente se conoci&oacute; su influencia en la fisiopatolog&iacute;a de la HTA, fundamentalmente basado en la acci&oacute;n de la angiotensina II (Ang II). Esta sustancia forma parte de la familia de factores neurohumorales, que junto a los propios efectos del aumento de PA son los responsables de la repercusi&oacute;n de la HTA sobre los &oacute;rganos diana (<a href="#7">7</a>). La Ang II es un p&eacute;ptido corto de 8 amino &aacute;cidos y constituye el principal agente vasopresor del Sistema Renina-Angiotensina-Aldosterona (SRAA). Se forma a partir de la angiotensina I mediante la acci&oacute;n de la enzima convertidora de angiotensina (ECA). Sin embargo, se ha demostrado que en algunos tejidos existen otras enzimas distintas a la ECA que tambi&eacute;n pueden convertir angiotensina I en Ang II, como quimasa, catepsina G o CAGE <b>(<a  href="#figura1">Figura 1</a>)</b>. Incluso se han descrito v&iacute;as alternativas que pueden formar Ang II a partir de angiotensin&oacute;geno, como t-PA, tonina, o catepsina. Por otra parte, la ECA es una enzima inespec&iacute;fico que adem&aacute;s de catalizar el paso de angiotensina 1 a Ang II, inactiva la v&iacute;a de degradaci&oacute;n de las quininas y de esta manera aumenta los niveles de bradiquinina circulante. Por todo ello, la acci&oacute;n de los IECA no s&oacute;lo se basa en la disminuci&oacute;n de la producci&oacute;n de Ang II, sino tambi&eacute;n en el aumento de niveles de bradiquinina. Adem&aacute;s los IECA no son capaces de inhibir por completo la producci&oacute;n de Ang II, ya que otras v&iacute;as enzim&aacute;ticas pueden producir Ang II de forma independiente de la ECA.    <br> </font></font></p>     <center><a name="figura1"></a><img  src="/img/fbpe/rcc/v4n3/2030i3.JPG" height="367" width="480"></center>     
<p></p>     <p><font face="Arial,Helvetica"><font size="-1">La Ang II ejerce su acci&oacute;n a trav&eacute;s de la inhibici&oacute;n de la adenilato-ciclasa, aumentando el calcio intracelular y act&uacute;a, tanto a nivel sist&eacute;mico como hormona circulante, como a nivel local como hormona aut&oacute;crina-par&aacute;crina. A nivel sist&eacute;mico tiene efectos vasoconstrictores y estimula la s&iacute;ntesis y liberaci&oacute;n de aldosterona y vasopresina, lo que produce aumento de las resistencias perif&eacute;ricas y retenci&oacute;n de sodio y agua; efectos todos ellos que contribuyen a aumentar la PA. A nivel local act&uacute;a en varios tejidos, como coraz&oacute;n, vasos sangu&iacute;neos o ri&ntilde;&oacute;n, produciendo proliferaci&oacute;n celular de miocitos, de m&uacute;sculo liso vascular y aumento de la formaci&oacute;n de col&aacute;geno con fibrosis intersticial y vascular, lo que constituye la principal causa de da&ntilde;o org&aacute;nico en una amplia variedad de enfermedades relacionadas con la HTA. En el tejido humano la Ang II tiene dos receptores espec&iacute;ficos principales: AT1 y AT2 que ejercen distintos efectos al ser estimulados. La respuesta biol&oacute;gica mediada por la Ang II depender&aacute; de la estimulaci&oacute;n de los correspondientes receptores en los &oacute;rganos diana (<a href="#8">8</a>). La mayor&iacute;a de los efectos no deseados de la Ang II son producidos a trav&eacute;s de la activaci&oacute;n de los receptores ATI, que son los m&aacute;s extensamente distribuidos y expresados en la mayor&iacute;a de los tejidos. Por tanto, el efecto principal de la Ang II en condiciones normales estar&iacute;a determinado fundamentalmente por la estimulaci&oacute;n de los receptores ATI. Estos receptores parecen jugar un papel clave en la regulaci&oacute;n de la PA (<a href="#9">9</a>).</font></font>     ]]></body>
<body><![CDATA[<br> &nbsp; </p>     <p><b><font face="Arial,Helvetica"><font size="-1">Bloqueo del SRAA en la Protecci&oacute;n Cardiovascular</font></font></b> </p>     <p><font face="Arial,Helvetica"><font size="-1">Si bien no existen dudas de que el hecho de disminuir las cifras tensionales en los pacientes hipertensos disminuye la incidencia de patolog&iacute;a cardiovascular, como lo demuestran el metaan&aacute;lisis de McMahon (<a href="#10">10</a>) o el "Blood Pressure Lowering Trialist Colaboration Group" (<a href="#11">11</a>), el objetivo del tratamiento en la HTA deber&iacute;a ser m&aacute;s ambicioso y buscar beneficios adicionales en t&eacute;rminos de protecci&oacute;n cardiovascular m&aacute;s all&aacute; del propio efecto de la reducci&oacute;n de la PA. En este sentido, los IECAs han demostrado, a trav&eacute;s de m&uacute;ltiples estudios, el beneficio que se obtiene en diferentes &oacute;rganos y tejidos mediante el bloqueo del SRAA. Estos estudios, aunque no fueron realizados espec&iacute;ficamente en la poblaci&oacute;n hipertensa, mostraron que los IECAs condicionan protecci&oacute;n renal (<a href="#12">12</a>), reducci&oacute;n de la morbi-mortalidad en enfermedad coronaria (<a href="#13">13,14</a>), en insuficiencia card&iacute;aca (<a href="#15">15</a>), en nefropat&iacute;a diab&eacute;tica (<a href="#16">16</a>) y en enfermedad cerebrovascular (<a href="#17">17</a>). Pero todos estos estudios fueron realizados comparando los IECAs frente a placebo; es decir, demuestran el beneficio de los IECAs cuando se estudia su efecto en comparaci&oacute;n con el comportamiento de pacientes sin tratamiento activo. Sin embargo, en estudios realizados en poblaciones de pacientes hipertensos en que se compar&oacute; los IECAs frente a otras clases de antihipertensivos, los IECA no han mostrado mejores resultados en morbi-mortalidad cardiovascular que los f&aacute;rmacos cl&aacute;sicos como betabloqueantes y/o diur&eacute;ticos (<a href="#18">18-20</a>). Estas evidencias sugieren la importancia del bloqueo del SRAA en la protecci&oacute;n de &oacute;rganos diana, pero quiz&aacute; la inhibici&oacute;n incompleta de la formaci&oacute;n de Ang II que producen los IECA podr&iacute;a no ser suficiente para reducir la morbi-mortalidad cardiovascular m&aacute;s que otros f&aacute;rmacos y diferenciarse de &eacute;stos. Por tanto surge la necesidad de buscar mol&eacute;culas que act&uacute;en bloqueando de un modo m&aacute;s selectivo y eficaz la Ang II y combinen efectos al menos tan favorables como los de los IECA, con un mejor perfil de tolerancia (<a href="#21">21</a>). A partir de estas premisas adquiere relevancia la aparici&oacute;n en el mercado de los antagonistas de receptores de Ang II (ARA II), que a trav&eacute;s de su mecanismo de acci&oacute;n proponen un bloqueo espec&iacute;fico de los efectos delet&eacute;reos de la Ang ll.</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">&nbsp;</font></font>     <br> <b><font face="Arial,Helvetica"><font size="-1">Papel de los ARA II en la Hipertensi&oacute;n Arterial</font></font></b> </p>     <p><font face="Arial,Helvetica"><font size="-1">Los ARA II ejercen su acci&oacute;n a trav&eacute;s de] bloqueo de los receptores AT1 de la Ang II de forma espec&iacute;fica y altamente selectiva y act&uacute;an inhibiendo los efectos cl&aacute;sicos desfavorables de Ang II. As&iacute;, los ARA II antagonizan la acci&oacute;n de la Ang II producida por cualquier v&iacute;a enzim&aacute;tica y no act&uacute;an sobre la degradaci&oacute;n de las quininas, con lo que no condicionan un aumento de sus niveles en sangre. Adem&aacute;s al bloquear los receptores ATI los ARA II permiten que la Ang II circulante se pueda ligar a los receptores AT2, lo que puede a&ntilde;adir un efecto adicional potencialmente muy beneficioso (<a href="#22">22</a>). Por otra parte, la bradiquinina circulante, adem&aacute;s de sus efectos vasodilatadores, parece estar asociada a ciertos efectos adversos como la tos seca, proceso que limita el uso de IECAs hasta en un 5-20% (<a  href="#23">23</a>). Los ARA lI, por tanto, est&aacute;n libres de esta reacci&oacute;n adversa tan caracter&iacute;stica de los IECA.</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">Existen estudios que muestran que los ARA II tienen una tolerabilidad mejor que la de los otros f&aacute;rmacos antihipertensivos. De hecho, Bloom public&oacute; en 1998 un an&aacute;lisis retrospectivo de 21.700 pacientes tratados con distintos f&aacute;rmacos antihipertensivos y analiz&oacute; la persistencia del tratamiento con la droga inicial a 12 meses de seguimiento. Este autor observ&oacute; que los pacientes medicados con un ARA II al a&ntilde;o ten&iacute;an una persistencia en el tratamiento superior al del resto de los pacientes que estaban tratados con otros f&aacute;rmacos (<a href="#24">24</a>). Posteriormente, Conlin public&oacute; un seguimiento de 15.000 pacientes del estudio de Bloom desde los 12 a los 48 meses, donde encontr&oacute; que la continuidad del tratamiento inicial segu&iacute;a siendo superior con ARA II (<a  href="#25">25</a>). Se ha demostrado que los ARA II presentan menos efectos adversos que los IECA, principalmente debido a la ausencia de tos, y la incidencia de reacciones adversas de estos f&aacute;rmacos es comparable al placebo (<a  href="#26">26-28</a>). Este excelente perfil de tolerabilidad puede ser fundamental para lograr una mayor adherencia al tratamiento(<a href="#29">29</a>). Por otra parte, la eficacia de los ARA II para disminuir la PA est&aacute; bien demostrada desde hace varios a&ntilde;os, tanto en HTA leve como moderada o severa (<a href="#30">30-33</a>) y en m&uacute;ltiples estudios comparativos estos f&aacute;rmacos han mostrado una eficacia antihipertensiva similar a la de IECAS, antagonistas del calcio o betabloqueantes (<a href="#34">34-39</a>). Por tanto, ante una eficacia antihipertensiva similar y un mejor perfil de tolerabilidad, los ARA II pueden considerarse una familia farmacol&oacute;gica de gran utilidad en el tratamiento actual de la HTA (<a href="#40">40</a>). As&iacute;, las recomendaciones de la OMS-SIH de 1999 establecen que los ARA II deben considerarse al igual que betabloqueantes, diur&eacute;ticos, antagonistas del calcio, IECA o alfabloqueantes como tratamiento de primera elecci&oacute;n en HTA (<a href="#5">5</a>).</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">Es posible que con las evidencias obtenidas con los ARA lI, en cuanto a eficacia y tolerabilidad en HTA y con los beneficios evidenciados en los pacientes con nefropat&iacute;a diab&eacute;tica (estudios IDNT y RENAAL) y en los pacientes con hipertrofia ventricular izquierda (estudio LIFE), las indicaciones de estos f&aacute;rmacos pueden ampliarse en un futuro inmediato. Es importante se&ntilde;alar como ejemplo de esto &uacute;ltimo, que la American Diabetes Association (ADA) ha decidido considerara los ARA II como tratamiento de primera elecci&oacute;n en los pacientes hipertensos con diabetes tipo 2, con microalbuminuria o proteinuria (<a href="#41">41</a>).</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">Hasta la fecha son siete los ARA II aprobados para HTA: losart&aacute;n, valsart&aacute;n, candesart&aacute;n, irbesart&aacute;n, eprosart&aacute;n, telmisart&aacute;n y olmesart&aacute;n <b>(<a href="#tabla1">Tabla 1</a>) </b>Estos f&aacute;rmacos tienen id&eacute;ntico mecanismo de acci&oacute;n y solo difieren en cuanto a sus caracter&iacute;sticas farmacol&oacute;gicas. Se han realizado diversos estudios comparativos analizando el efecto sobre la PA. Los resultados obtenidos han mostrado algunas diferencias entre ellos en cuanto a potencia antihipertensiva (<a  href="#42">42-44</a>). Sin embargo, un metan&aacute;lisis que agrup&oacute; a 11.281 pacientes de 43 estudios diferentes con ARA II no mostr&oacute; diferencias significativas en cuanto a la reducci&oacute;n de PA alcanzada con los distintos ARA lI, lo que sugiere que los ARA II podr&iacute;an tener una eficacia similar cuando se administran a las dosis usuales recomendadas (<a href="#45">45</a>).</font></font>     <br> </p>     ]]></body>
<body><![CDATA[<p>    <br> </p>     <center><a name="tabla1"></a>&nbsp;<b><font face="Arial,Helvetica"><font  size="-1"><a href="file:///C:/img/fbpe/rcc/v4n3/2030i01.JPG"><img  src="/img/fbpe/rcc/v4n3/2030i01.JPG" title="" alt=""  style="border: 0px solid ; width: 600px; height: 191px;"></a></font></font></b></center>     
<p>&nbsp;     <br> &nbsp; </p>     <p><b><font face="Arial,Helvetica"><font size="-1">Estudios de Morbi-Mortalidad en Hipertensi&oacute;n con ARA II</font></font></b> </p>     <p><font face="Arial,Helvetica"><font size="-1">La incidencia de complicaciones cardiovasculares relacionadas con la HTA sigue siendo alta, a pesar de las numerosas alternativas terap&eacute;uticas disponibles en el mercado y a las diversas estrategias de tratamiento instauradas. En los &uacute;ltimos a&ntilde;os se han realizado varios estudios sobre morbi-mortalidad cardiovascular en el paciente hipertenso comparando distintos f&aacute;rmacos entre s&iacute;. Principalmente se compararon los efectos de los f&aacute;rmacos "modernos" como antagonistas del calcio e IECAs frente al de los f&aacute;rmacos "cl&aacute;sicos" como betabloqueantes y diur&eacute;ticos. Al contrario de lo que se pensaba, no se observaron diferencias significativas entre los f&aacute;rmacos en t&eacute;rminos de morbi-mortalidad cardiovascular (<a href="#19">19</a>,<a  href="#46">46-49</a>). Estos hallazgos parecen indicar que todos los antihipertensivos son similares y el &uacute;nico efecto beneficioso es el propio de la reducci&oacute;n de PA. En pacientes hipertensos de muy alto riesgo cardiovascular, como son los pacientes con nefropat&iacute;a diab&eacute;tica, los estudios IDNT y RENAAL realizados con irbesart&aacute;n y losart&aacute;n respectivamente, demostraron una reducci&oacute;n significativa de la morbi-mortalidad cardiovascular. En ambos estudios la variable principal de eficacia fue la combinaci&oacute;n de muerte, tiempo de duplicaci&oacute;n de creat&iacute;n&iacute;na s&eacute;rica y ca&iacute;da en insuficiencia renal terminal. En el estudio IDNT los pacientes se distribuyeron en tres grupos de tratamiento: placebo, amiodipino e irbesart&aacute;n. En este estudio se demostr&oacute; que el tratamiento con irbesart&aacute;n a los 2.6 a&ntilde;os de tratamiento produjo una reducci&oacute;n del riesgo relativo del 23% (p=0.006) respecto a amiodipino y del 20% (p=0.024) respecto a placebo, siendo los resultados con amiodipino y placebo similares (<a href="#50">50</a>). El estudio RENAAL compar&oacute; el tratamiento basado en losart&aacute;n frente a placebo. Tambi&eacute;n se confirm&oacute;, de forma similar al IDNT, una reducci&oacute;n del riego relativo del 16% (p=0.024) en el grupo tratado con el ARA II (<a  href="#51">51</a>). El hecho de que en dos ensayos cl&iacute;nicos similares con dos ARA II diferentes los resultados sean tan parejos confirma los hallazgos y establece la utilidad de estos f&aacute;rmacos en la protecci&oacute;n cardio-vasculo-renal del paciente con nefropat&iacute;a diab&eacute;tica.</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">Tres son los grandes estudios de morbi-mortalidad que analizan el papel de los ARA II en HTA: el estudio LIFE (ya publicado), el estudio SCOPE (presentado pero a&uacute;n no publicado) y el estudio VALUE (a&uacute;n en marcha)(<b><a href="#tabla2">Tabla 2</a></b>) Hasta ahora la evidencia disponible es la que proviene del estudio LIFE, el &uacute;nico que ya ha sido publicado (<a href="#52">52</a>). El estudio LIFE se dise&ntilde;&oacute; hace varios a&ntilde;os con la hip&oacute;tesis de que el antagonismo selectivo de los receptores ATI de la Ang II con losart&aacute;n podr&iacute;a ser m&aacute;s eficaz que el betabloqueo con atenolol para reducir la<b> </b>morbilidad y mortalidad cardiovascular en los pacientes con HTA (PA sist&oacute;lica 160-190 y/o diast&oacute;lica 95-110) y signos electrocardiogr&aacute;ficos de hipertrofia ventricular izquierda, detectada por criterios del producto duraci&oacute;n-voltaje de Cornell (&gt;2.440 mmxmsg) o por criterios de voltaje de Sokolow-Lyon (&gt;38 mm). Se realiz&oacute; una comparaci&oacute;n aleatorizada, doble ciego y con doble enmascaramiento de los efectos a largo plazo de losart&aacute;n con los de atenolol. La variable principal de valoraci&oacute;n fue la morbilidad y la mortalidad cardiovasculares, que se defini&oacute; por la combinaci&oacute;n de muerte de causa cardiovascular, infarto agudo de miocardio e ictus (<a href="#46">46</a>). Fueron randomizados 9.194 pacientes con una edad media de 67 a&ntilde;os y una PA media de 174.4/98.7 mm Hg y se realiz&oacute; un seguimiento m&iacute;nimo de 4 a&ntilde;os. Basalmente, cerca del 16% hab&iacute;a tenido manifestaciones de enfermedad coronaria, 8% ictus previo o accidente isqu&eacute;mico transitorio y el 13% eran diab&eacute;ticos (<a href="#53">53,54</a>). En estos pacientes los betabloqueantes son una opci&oacute;n adecuada para realizar la comparaci&oacute;n con losart&aacute;n, ya que estos f&aacute;rmacos son de primera elecci&oacute;n en el tratamiento de la HTA, tienen una eficacia antihipertensiva similar a losart&aacute;n (<a href="#55">55</a>) y han demostrado disminuir la morbilidad y mortalidad al compararse con placebo (<a href="#56">56</a>). A los 12 meses de seguimiento, la PA hab&iacute;a disminuido a 150.5/85.1 mm Hg pero solamente el 23% de los pacientes estaba tomando el f&aacute;rmaco de estudio en monoterapia (<a href="#57">57</a>). Esta tendencia se mantuvo y al finalizar el estudio s&oacute;lo el 9-10% de los pacientes estaban tratados solamente con la medicaci&oacute;n inicial (50 mg atenolol o 50 mg de losart&aacute;n), lo que enfatiza la necesidad de la politerapia en la gran mayor&iacute;a de los pacientes hipertensos.    <br> </font></font></p>     <center><a name="tabla2"></a><b><font face="Arial,Helvetica"><font  size="-1"><a href="file:///C:/img/fbpe/rcc/v4n3/2030i02.JPG"><img  src="/img/fbpe/rcc/v4n3/2030i02.JPG" title="" alt=""  style="border: 0px solid ; width: 600px; height: 362px;"></a></font></font></b></center>     
]]></body>
<body><![CDATA[<p></p>     <p><font face="Arial,Helvetica"><font size="-1">A los 5 a&ntilde;os se observ&oacute; que el grupo de pacientes con tratamiento basado en losart&aacute;n mostr&oacute; una reducci&oacute;n relativa del riesgo del 13% respecto al grupo de atenolol de aparici&oacute;n de muerte cardiovascular, infarto de miocardio o ictus (508 pacientes del grupo losart&aacute;n y 588 pacientes del grupo atenolol, p=0.021). <b>(<a href="#figura2">Figura 2</a>) </b>Esta reducci&oacute;n del riesgo fue debida a una significativa reducci&oacute;n del 25% en la incidencia de ictus (p=0.001), ya que la aparici&oacute;n de muerte cardiovascular y de infarto de miocardio fue similar en ambos grupos de tratamiento. La reducci&oacute;n del riesgo era mayor (14.6%, p= 0,009) sin introducir un ajuste respecto a la puntuaci&oacute;n de riesgo de Framingham y el grado de hipertrofia ventricular izquierda (HVI) por ECG en situaci&oacute;n basal. En cuanto a la HTA, hubo una reducci&oacute;n de PA importante y muy similar en ambos grupos (30.2/16.6 mm Hg en el grupo losart&aacute;n y 29.1/16.8 mm Hg en el grupo atenolol). Esto evidencia que los beneficios adicionales obtenidos por el ARA II son independientes del puro efecto sobre la PA. Secundariamente el estudio LIFE mostr&oacute; una reducci&oacute;n significativa del 25% (p&lt;0.001) del riesgo de padecer diabetes de nueva aparici&oacute;n en los pacientes tratados con losart&aacute;n frente a los tratados con atenolol. Se observ&oacute; adem&aacute;s una mayor regresi&oacute;n de la hipertrofia ventricular izquierda en el grupo de losart&aacute;n. Con losart&aacute;n se observ&oacute; un reducci&oacute;n del 10% y del 16% con los criterios de Comell y de Sokolow-Lyon, mientras que con atenolol la reducci&oacute;n fue de 4.4% y 9% respectivamente (en ambos casos, p&lt;0.0001). Hay que destacar que &eacute;sta mayor capacidad de regresi&oacute;n de la hipertrofia ventricular no explica todo el efecto favorable del ARA II respecto a atenolol. Se demostr&oacute; tambi&eacute;n una menor incidencia de efectos adversos en el grupo de losart&aacute;n (<a href="#52">52</a>). En el subestudio del LIFE que evalu&oacute; la morbilidad y mortalidad cardiovascular en 1.195 pacientes diab&eacute;ticos, los beneficios de losart&aacute;n fueron a&uacute;n m&aacute;s pronunciados en todas las variables analizadas, sobre todo en un peque&ntilde;o grupo de pacientes que no hab&iacute;an sido tratados por HTA antes del estudio (<a  href="#58">58</a>). En este subgrupo de pacientes se observ&oacute; una reducci&oacute;n del riesgo en la variable primaria del 24% (103 pacientes asignados a losart&aacute;n y 139 asignados a atenolol, p=0.031). Adem&aacute;s se observ&oacute; una reducci&oacute;n significativa del 37% de riesgo de muerte cardiovascular (fallecieron 38 y 61 pacientes de los grupos de losart&aacute;n y atenolol respectivamente, p=0.028) y una reducci&oacute;n del 39% del riesgo de muerte por cualquier causa (64 y 104 muertes, p=0.002). Estos hallazgos contrastan con los del estudio UKPDS, en el que se compar&oacute; el efecto de captopril y de atenolol en pacientes hipertensos diab&eacute;ticos. En este estudio no se observaron diferencias significativas en morbi-mortalidad entre el IECA y el betabloqueante (<a href="#19">19</a>). Por tanto, los beneficios observados en el LIFE con un ARA lI, no observados antes con IECA, distinguen el efecto de estas dos clases farmacol&oacute;gicas.    <br> </font></font></p>     <center><a name="figura2"></a><b><font face="Arial,Helvetica"><font  size="-1"><a href="file:///C:/img/fbpe/rcc/v4n3/2030i04.JPG"><img  src="/img/fbpe/rcc/v4n3/2030i04.JPG" title="" alt=""  style="width: 600px; height: 390px;"></a></font></font></b></center>     
<p></p>     <p><font face="Arial,Helvetica"><font size="-1">Tambi&eacute;n se ha realizado un subestudio del LIFE en el subgrupo de pacientes con hipertensi&oacute;n sist&oacute;lica aislada, alrededor del 15% del total. Este subestudio fue publicado recientemente en JAMA y los resultados demostraron un beneficio a&uacute;n mayor en esta poblaci&oacute;n que en los diab&eacute;ticos. La variable primaria se redujo en 25%, a punto de alcanzar significaci&oacute;n estad&iacute;stica (p=0.06), el riesgo de ictus se redujo de forma significativa en un 40% y el de muerte cardiovascular en un 46%. Adem&aacute;s losart&aacute;n disminuy&oacute; la hipertrofia ventricular izquierda m&aacute;s que atenolol (p=0,001) y fue mejor tolerado (<a href="#59">59</a>).</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">Un an&aacute;lisis secundario del estudio LIFE examin&oacute; un aspecto muy relevante cl&iacute;nicamente: la influencia del control de PA sobre la regresi&oacute;n de la hipertrofia ventricular izquierda determinada por ecocardiograf&iacute;a, tras dos a&ntilde;os de tratamiento antihipertensivo. Se realizaron controles ecocardiogr&aacute;ficos al a&ntilde;o y a los dos a&ntilde;os y los resultados mostraron que si bien la PA disminu&iacute;a significativamente durante el primer a&ntilde;o, no se modificaba significativamente durante el segundo. Sin embargo, la regresi&oacute;n de la hipertrofia fue persistente y significativa durante los dos a&ntilde;os, por lo que disminuy&oacute; la prevalencia de hipertrofia conc&eacute;ntrico y exc&eacute;ntrica y aument&oacute; la proporci&oacute;n de pacientes con geometr&iacute;a ventricular normal. Esto muestra los beneficios adicionales m&aacute;s all&aacute; del efecto de reducci&oacute;n de PA y demuestra que la m&aacute;xima regresi&oacute;n de la hipertrofia requerir&iacute;a como m&iacute;nimo dos a&ntilde;os de tratamiento ant&iacute;hipertensivo (<a href="#60">60,61</a>).</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">En los &uacute;ltimos meses se han publicado diversos subestudios del estudio LIFE que han puesto en evidencia los beneficios del tratamiento antihipertensivo sobre la funci&oacute;n sist&aacute;lica (<a href="#62">62</a>), la funci&oacute;n diast&aacute;lica (<a href="#63">63</a>), correlaci&oacute;n de la presi&oacute;n de pulso durante el tratamiento antihipertensivo (<a href="#64">64</a>), correlaci&oacute;n del tama&ntilde;o de la aur&iacute;cula izquierda (<a href="#65">65</a>), y la relaci&oacute;n del &iacute;ndice albuminuria/creatinina con la funci&oacute;n y estructura del ventriculo (<a href="#66">66</a>).</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1"><u>M&aacute;s all&aacute; de todos estos hallazgos el resultado m&aacute;s importante</u> <u>del LIFE fue que por primera vez una clase farmacol&oacute;gica, los ARA II (en concreto losart&aacute;n) se ha mostrado superior a otra clase de antihipertensivos (en este caso betabloqueantes, y en concreto atenolol).</u> Probablemente el efecto sobre la PA no haya tenido mayor influencia en la incidencia de eventos cardiovasculares, y fundamentalmente de ictus, ya que en ambos grupos la PA fue muy similar. De hecho, la PA sist&oacute;lica en el grupo de losart&aacute;n fue 1.3 mmhg m&aacute;s baja que en el grupo de atenolol y la PA diast&oacute;lica 0.4 mmhg m&aacute;s alta en la &uacute;ltima vista realizada. Estos hallazgos nos llevan a que la presi&oacute;n de pulso final fue algo menor en el grupo de losart&aacute;n. Este dato podr&iacute;a tener alguna implicaci&oacute;n pronostica en la aparici&oacute;n de ictus, aunque dif&iacute;cilmente puede explicar los beneficios alcanzados con el ARA li, ya que la diferencia de presi&oacute;n entre ambos grupos es muy peque&ntilde;a. Por otra parte, en el subgrupo de pacientes diab&eacute;ticos, &eacute;stos ten&iacute;an una mayor presi&oacute;n de pulso que la poblaci&oacute;n general y sin embargo la incidencia de ictus se dio en un peque&ntilde;o numero de pacientes y las diferencias entre los grupos de tratamiento no fueron significativas. Es interesante resaltar que en el grupo de pacientes randomizados a atenolol hab&iacute;a 25 pacientes m&aacute;s con fibrilaci&oacute;n auricular, lo que podr&iacute;a tener alguna influencia en la aparici&oacute;n de ictus durante el seguimiento.</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">Los mecanismos por lo que los ARA II han mostrado ser especialmente &uacute;tiles en los pacientes de mayor riesgo no son bien conocidos. Quiz&aacute; pueda influir el probable efecto beneficioso de estos f&aacute;rmacos en la disfunci&oacute;n endotelial y en los procesos de arterioscierosis. De todas maneras se ha sugerido que los resultados obtenidos en el LIFE podr&iacute;an quiz&aacute; ser extrapolados tambi&eacute;n a pacientes de bajo riesgo (<a href="#67">67</a>). En cualquier caso, en la realidad de la pr&aacute;ctica cl&iacute;nica diaria en nuestro medio, es muy infrecuente la HTA de bajo riesgo. De hecho en un estudio recientemente publicado se demuestra que la mayor&iacute;a de los pacientes hipertensos que acuden actualmente a la consulta de atenci&oacute;n primaria en nuestro pa&iacute;s son ya de riesgo alto o muy alto siguiendo la estratificaci&oacute;n propuesta por la OMS-SIH de 1999 (<a  href="#68">68</a>). Se ha sugerido que los beneficios observados con losart&aacute;n pudieran ser superiores si se administrara una dosis constante de 100mg, ya que en el estudio LIFE menos del 50% alcanzaron esta dosificaci&oacute;n y se ha visto que algunos ARA II tienen mayores beneficios a sus dosis m&aacute;ximas (<a href="#69">69</a>). Habr&iacute;a que se&ntilde;alar que la mayor&iacute;a de los pacientes randomizados fueron de raza blanca y debido a la alta prevalencia de HTA en individuos de raza negra ser&iacute;a importante determinar si estos hallazgos pueden ser extrapolables a este grupo &eacute;tnico.</font></font> </p>     ]]></body>
<body><![CDATA[<p><font face="Arial,Helvetica"><font size="-1">El estudio SCOPE es el primer ensayo cl&iacute;nico realizado a gran escala para evaluar los efectos del tratamiento con un ARA II (candesart&aacute;n) sobre eventos cardiovasculares mayores (infarto de miocardio, ictus y mortalidad cardiovascular) y funci&oacute;n cognitiva en pacientes ancianos (<a href="#70">70</a>). Se trata de un estudio prospectivo, aleatorizado, doble ciego en el que se incluyeron 4.937 pacientes de ambos sexos de 70 a 89 a&ntilde;os de edad (76 a&ntilde;os de media), con HTA (PA sist&oacute;lica 160-179 mmhg y/o diast&oacute;lica 90/99 mmhg) y de riesgo cardiovascular principalmente medio y alto. Los pacientes se distribuyeron aleatoriamente a candersart&aacute;n o placebo. Hay que destacar que debido a la necesidad de tratar la HTA en algunos pacientes y los cambios que han venido sucediendo en cuanto a los objetivos de control de PA, en el grupo placebo casi el 85% de los pacientes estaba con medicaci&oacute;n antihipertensiva, por lo que realmente no puede considerarse que ese grupo de pacientes estuviera en placebo. Los resultados preliminares de este estudio fueron presentados en el &uacute;ltimo Congreso de la Sociedad Europea de HTA-Sociedad internacional de HTA (junio 2002) y est&aacute;n a&uacute;n pendientes de publicaci&oacute;n. Tras un seguimiento m&iacute;nimo de 3 a&ntilde;os se demostr&oacute; una reducci&oacute;n no significativa en el riesgo de acontecimientos cardiovasculares mayores en pacientes tratados con ARA II. Sin embargo, s&iacute; se observ&oacute; una reducci&oacute;n significativa del 28% del riesgo de ictus (p=0.04) en el grupo de pacientes tratados con candersart&aacute;n. El tercer gran ensayo cl&iacute;nico en HTA con ARA II esta a&uacute;n en marcha, es el estudio VALUE (<a  href="#71">71</a>). Se trata de un estudio prospectivo, multic&eacute;ntrico, randomizado, doble ciego, con dos ramas de tratamiento: amiodipino y valsart&aacute;n. La hip&oacute;tesis es que a los mismos niveles de control de PA, el ARA II ser&iacute;a m&aacute;s efectivo que amiodipino en disminuir la incidencia de infarto de miocardio, insuficiencia card&iacute;aca congestivo y muerte card&iacute;aca. El seguimiento del mismo ser&aacute; hasta que 1.450 pacientes experimenten alguna variable principal, y la previsi&oacute;n es que eso pueda ocurrir a finales del 2003. Se han incluido m&aacute;s de 15.000 hipertensos mayores de 50 a&ntilde;os con PA sist&oacute;lica 160-210 y/o diast&oacute;lica 95-115 mmhg y riesgo cardiovascular alto o muy alto. De hecho, los pacientes que han sido incluidos en este estudio son una poblaci&oacute;n de riesgo muy alto: 33% son dislip&eacute;micos, 32% de diab&eacute;ticos, 24% fumadores y un alto n&uacute;mero presentan enfermedad cardiovascular, 46% enfermedad coronar&iacute;a, 20% con enfermedad cerebrovascular y 14% enfermedad vascular perif&eacute;rico (<a href="#72">72</a>). Teniendo en cuenta el n&uacute;mero de pacientes y el elevado porcentaje de factores de riesgo de los mismos se espera una variada e importante informaci&oacute;n al finalizar este estudio.</font></font> </p>     <p><font face="Arial,Helvetica"><font size="-1">Podemos decir como <b>conclusi&oacute;n </b>que a la buena eficacia y excelente tolerabilidad que han demostrado los ARA II en el tratamiento de la HTA se ha sumado un hecho trascendental como es la disminuci&oacute;n de la morbi-mortalidad cardiovascular superior a la de otros f&aacute;rmacos de probada eficacia antihipertensiva. Es de esperar que en un futuro pr&oacute;ximo las indicaciones de los ARA II sean m&aacute;s amplias que las actuales, en la medida que estos f&aacute;rmacos sigan demostrando sus beneficios en la protecci&oacute;n cardiovascular m&aacute;s all&aacute; del simple efecto del control de PA</font></font>     <br> &nbsp; </p> &nbsp;     <br> <b><font face="Arial,Helvetica"><font size="-1">Bibliograf&iacute;a</font></font></b>     <!-- ref --><p><a name="1"></a><font face="Arial,Helvetica"><font size="-1"><b>1- </b>Benegas JR , Rodr&iacute;guez-Artalejo F , De la Cruz Troca JJ , Guallar-Castili&oacute;n P , Del Rey Calero J. La presi&oacute;n arterial en Espa&ntilde;a. Distribuci&oacute;n, grado de conocimiento, control y beneficios de una reducci&oacute;n en los niveles medios de presi&oacute;n arterial. Hipertensi&oacute;n 1999; 32: 908-1.002.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743850&pid=S1409-4142200200030000600001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="2"></a><font face="Arial,Helvetica"><font size="-1"><b>2- </b>Gonz&aacute;lez Juanatey JR, Alegria Ezquerra E, Lozano Vidal JV, llisterri Caro JL, Garc&iacute;a Acu&ntilde;a JM y Gonz&aacute;lez Maqueda I. Impacto de la hipertensi&oacute;n en las cardiopat&iacute;as en Espa&ntilde;a. Estudio CARDIOTENS 1999. Rev Esp Cardiol 2001; 54: 139-149.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743851&pid=S1409-4142200200030000600002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="3"></a><font face="Arial,Helvetica"><font size="-1"><b>3- </b>Ministerio de Sanidad y Consumo y Sociedad -Liga Espa&ntilde;ola de Hipertensi&oacute;n arterial. Consenso para el control de la presi&oacute;n arterial en Espa&ntilde;a. Madrid, 1996.</font></font> </p>     <!-- ref --><p><a name="4"></a><font face="Arial,Helvetica"><font size="-1"><b>4- </b>Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC-VI). Arch lntern Med 1997; 157: 2313-2446.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743853&pid=S1409-4142200200030000600004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="5"></a><font face="Arial,Helvetica"><font size="-1"><b>5- </b>Guidelines Subcomm&iacute;ttee. 1999 Worid Health Organization lnternational Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743854&pid=S1409-4142200200030000600005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="6"></a><font face="Arial,Helvetica"><font size="-1"><b>6- </b>Barrios V, Ruilope LM. Hipertension with left ventricular hypertrophy/diastolic dysfunction. En: Sleight P, Bakris G, Mancia G, Opie FML, eds. Clinica cases in hypertension. Specific treatment strategies. II. Richmond upon Thames (Reino Unido): PAN Communications, 2000; 16-22</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743855&pid=S1409-4142200200030000600006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="7"></a><font face="Arial,Helvetica"><font size="-1"><b>7- </b>Laragh LH, Sealy JE. The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. En: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. Nueva York: Raven Press, 1990: 1329-1348.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743856&pid=S1409-4142200200030000600007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="8"></a><font face="Arial,Helvetica"><font size="-1"><b>8-</b> Zitnay C, Siragy HM. Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atheroscierosis. Miner Electrolyte Metab 1998; 24: 362-370.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743857&pid=S1409-4142200200030000600008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="9"></a><font face="Arial,Helvetica"><font size="-1"><b>9- </b>Bermam MA, Waih MF, Sowers JR: Angiotensin II biochemistryan physiologhy. Update on angiotensin II receptor blockers. Cardiovasc Rev 1997; 15: 75-100.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743858&pid=S1409-4142200200030000600009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="10"></a><font face="Arial,Helvetica"><font size="-1"><b>10- </b>Mac Mahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomised controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967-978.</font></font> </p>     <!-- ref --><p><a name="11"></a><font face="Arial,Helvetica"><font size="-1"><b>11- </b>Neal B, Mac Mahon S, Chapman N et al. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-iowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure lowering Treatment Trialists Collaboration. Lancet 2000; 356:1955-1964.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743860&pid=S1409-4142200200030000600011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="12"></a><font face="Arial,Helvetica"><font size="-1"><b>12- </b>Maschio G, Alberti D, Janin G et al. The angiotensinconverting-enzyme inhibition in progressive renal insufficiency Study Group. N Engl J Med 1996; 334: 939-945.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743861&pid=S1409-4142200200030000600012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="13"></a><font face="Arial,Helvetica"><font size="-1"><b>13- </b>Pfeffer MA, Braunwald E, Moy&eacute; LA, Basta L, Brown EJ, Cuddy TE, et al. on behalf of the SAVE lnvestigators. The effect of captopril of morbidity and mortality in patients with left ventricular dysfunction following myocardial infarction. Results of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med 1992; 327: 669-677.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743862&pid=S1409-4142200200030000600013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="14"></a><font face="Arial,Helvetica"><font size="-1"><b>14-</b> The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-153</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743863&pid=S1409-4142200200030000600014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="15"></a><font face="Arial,Helvetica"><font size="-1"><b>15- </b>The SOLVD lnvestigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-691.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743864&pid=S1409-4142200200030000600015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="16"></a><font face="Arial,Helvetica"><font size="-1"><b>16- </b>Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743865&pid=S1409-4142200200030000600016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="17"></a><font face="Arial,Helvetica"><font size="-1"><b>17- </b>PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-iowering regimen among 6.105 individuas with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743866&pid=S1409-4142200200030000600017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="18"></a><font face="Arial,Helvetica"><font size="-1"><b>18- </b>Hansson L, Lindholm LH, Niskanen L , Lanke J , Hedner T , Nikiason A , Luomanmaki K , Dahioff B , de Faire U , Morlin C , Kariberg BE , Wester PO , Bjorck J-E. Effect angiotensin-convertingenzyme inhibition compared with convencional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 61 l616.</font></font> </p>     <!-- ref --><p><a name="19"></a><font face="Arial,Helvetica"><font size="-1"><b>19- </b>UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713720.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743868&pid=S1409-4142200200030000600019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="20"></a><font face="Arial,Helvetica"><font size="-1"><b>20- </b>Hansson L, Lindhoim LH, Ekbom T, Dahioff B, lanke I, Schersten B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderiy patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756</font></font> </p>     <!-- ref --><p><a name="21"></a><font face="Arial,Helvetica"><font size="-1"><b>21- </b>Barrios V, Jimenez JJ. Coraz&oacute;n e hipertensi&oacute;n. En: RuilopeLM, ed. Nuevas fronteras en hipertensi&oacute;n. Barcelona: Doyma, 1998; 3: 29-63.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743870&pid=S1409-4142200200030000600021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="22"></a><font face="Arial,Helvetica"><font size="-1"><b>22- </b>Ruilope LM, Barrios V. Pharmacologic treatment in hypertensive heart disease. En: Crawford MH, Di Marco JP, eds. Cardiology. London: Mosby, 2001; 8.1-8.8.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743871&pid=S1409-4142200200030000600022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="23"></a><font face="Arial,Helvetica"><font size="-1"><b>23- </b>lsraili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting-enzyme inhibitor therapy: a review of the literature and pathophysiology. Am Intern Med 1992., 117: 234242.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743872&pid=S1409-4142200200030000600023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="24"></a><font face="Arial,Helvetica"><font size="-1"><b>24- </b>Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-681.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743873&pid=S1409-4142200200030000600024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="25"></a><font face="Arial,Helvetica"><font size="-1"><b>25- </b>Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating theraphy with the angiotensina II receptor antagonist losart&aacute;n versus other antihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743874&pid=S1409-4142200200030000600025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="26"></a><font face="Arial,Helvetica"><font size="-1"><b>26- </b>Paster RZ, Snavely DB, Swett AR, Draper RA, Goldberg Al, Soffer BA, Swett CS. Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting-enzyme inhibitors. Clin Ther 1998; 20: 978-989.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743875&pid=S1409-4142200200030000600026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="27"></a><font face="Arial,Helvetica"><font size="-1"><b>27- </b>Black HR, Graff A, Shute D, Stoltz R, Ruff D, levine J, Shi Y, Mallows S: Valsartan, a new angiotensin II antagonist of the treatment of essential hypertension. Efficacy, tolerability and safety compared to an angiotensin inhibitor. lisinopril. J Hum Hypertens 1997; 11: 483-489.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743876&pid=S1409-4142200200030000600027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="28"></a><font face="Arial,Helvetica"><font size="-1"><b>28- </b>Belcher G, Hubner R, George M, Elmfeldt D, lunde H: Candersartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 1 1: 585-589.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743877&pid=S1409-4142200200030000600028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="29"></a><font face="Arial,Helvetica"><font size="-1"><b>29- </b>Barrios V, Navarro A, Esteras A, Luque M, Romero J, Tamargo, J, Prieto L, Carrasco JL, Herranz I, Navarro-Cid J and Ruilope LM. Antihypertensive efficacy and tolerability of lercarnidipine in daily clinical practice. The ELYPSE study. Blood Pressure 2002; 11: 95-100</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743878&pid=S1409-4142200200030000600029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="30"></a><font face="Arial,Helvetica"><font size="-1"><b>30- </b>Sever R Candersartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 1997; 11 (suppl 2): 591-595.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743879&pid=S1409-4142200200030000600030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="31"></a><font face="Arial,Helvetica"><font size="-1"><b>31- </b>Johnston Cl. Angiotensin receptor antagonist: focus on losartan. Lancet 1995; 346: 1403-1407.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743880&pid=S1409-4142200200030000600031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="32"></a><font face="Arial,Helvetica"><font size="-1"><b>32- </b>Gillis JC, Markham A. irbesartan: A review o&iacute; its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-90.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743881&pid=S1409-4142200200030000600032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="33"></a><font face="Arial,Helvetica"><font size="-1"><b>33- </b>Markham A, Goa KL. Valsartan: A review of its pharmacology and therapeut&iacute;c use in essential hypertension. Drugs 1997; 54: 299-311.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743882&pid=S1409-4142200200030000600033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="34"></a><font face="Arial,Helvetica"><font size="-1"><b>34- </b>Black HR, Graff A, Shute D, Stoiz R, Ruff D, levine J, Shi Y, Mallows S: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. Efficacy, tolerability and safety compared to an angiotensin- converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997; 11: 483-489.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743883&pid=S1409-4142200200030000600034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="35"></a><font face="Arial,Helvetica"><font size="-1"><b>35- </b>Tikkanen I, Omvik P, Jensen HA, for the Scandinavian Study Group: Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-1351.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743884&pid=S1409-4142200200030000600035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="36"></a><font face="Arial,Helvetica"><font size="-1"><b>36- </b>Mimran A, Ruilope LM, Kerwin L, Nys M, Owens D, Kassler-Taub K, Osbakken M: A randomised, double blind comparison of the angiotensin II receptor antagonist irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203-208.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743885&pid=S1409-4142200200030000600036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="37"></a><font face="Arial,Helvetica"><font size="-1"><b>37- </b>Kariberg BE, Lins LE, and Hermansson K, for the TEES Study Group. Efficacy and Safety of Teimisartan, a selectiva AT I receptor antagonist, compared with enalapril in ederly patients with Primary hypertension. J Hypertens 1999; 17: 293-302.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743886&pid=S1409-4142200200030000600037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="38"></a><font face="Arial,Helvetica"><font size="-1"><b>38- </b>Dahiof B, Keller S, Makris L, Goldberg Al, Sweet CS, Lim NY: Efficacy and tolerability of losartan potassium and atenolol in patients with mild or moderate essential hypertension. Am J Hypertens 1995; 8: 578- 583.</font></font> </p>     <!-- ref --><p><a name="39"></a><font face="Arial,Helvetica"><font size="-1"><b>39- </b>Corea L, Cardoni O, Fogari R, lnnocenti P, Porcellati C, Providenza M, Meilenbrock S, Sullivan J, Bodin F: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. A comparative study of the efficacy and safety agonist amiodipine. Clin Pharm Ther 1996; 60: 341-346.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743888&pid=S1409-4142200200030000600039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="40"></a><font face="Arial,Helvetica"><font size="-1"><b>40- </b>Lombera F, Barrios V, Soria F, Placer L, Cruz JM, Tom&aacute;s L, et al. Gu&iacute;as de pr&aacute;ctica cl&iacute;nica de la Sociedad Espa&ntilde;ola de Cardiolog&iacute;a en hipertensi&oacute;n arterial. Rev Esp Cardiol 2000; 53: 66-90.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743889&pid=S1409-4142200200030000600040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="41"></a><font face="Arial,Helvetica"><font size="-1"><b>41- </b>American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002; 25(Suppl): S85-S89.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743890&pid=S1409-4142200200030000600041&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="42"></a><font face="Arial,Helvetica"><font size="-1"><b>42-</b> Kassier-Taub K, Little John T, Elliott W, Ruddy T, AdLer E: Comparative efficacy of two angiotensin II receptor antagonists, irbersartan and losartan, in mild to moderate hypertension. Am J Hypertens 1998; 11: 445- 453.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743891&pid=S1409-4142200200030000600042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="43"></a><font face="Arial,Helvetica"><font size="-1"><b>43- </b>Andersson OK, Neldom S: The antihypertensive effect and tolerability of candersartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-59.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743892&pid=S1409-4142200200030000600043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="44"></a><font face="Arial,Helvetica"><font size="-1"><b>44- </b>Oparil S. Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists. J Hum Hypertens 2002; 16(suppl 2): 17-23.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743893&pid=S1409-4142200200030000600044&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="45"></a><font face="Arial,Helvetica"><font size="-1"><b>45- </b>Conlin P, Spence B, Ribeiro A, Saito I, Benedict C, Bunt M. Angiotensin II antagonist for hypertension: Are there differences in efficacy? Am J Hypertens 2000; 13: 418- 426.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743894&pid=S1409-4142200200030000600045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="46"></a><font face="Arial,Helvetica"><font size="-1"><b>46- </b>Hansson L, Lindhoim LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahiof B, de Faire U, Morlin C, Kariberg BE, Wester PO, Bjorck J-E. Effect angiotensin-converting-enzyme inhibition compared with convencional therapy on cardiovascular morbidity and mortality in hypertension: Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.</font></font> </p>     ]]></body>
<body><![CDATA[<!-- ref --><p><a name="47"></a><font face="Arial,Helvetica"><font size="-1"><b>47- </b>Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Mordidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the internacional Nifedipine GITS study: lntervention as a goal in hypertension Treatment (INSIGHT). lancet 2000; 356: 366-372.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743896&pid=S1409-4142200200030000600047&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="48"></a><font face="Arial,Helvetica"><font size="-1"><b>48- </b>Hansson L, Hedner T, Lund-Johansen P, Kjeidsen S, Lindhoim LH, Syvertsen JO, Lanke J, de Faire U, Dahiof B, Kariberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and Beta-blockers on cardiocascular morbidity and morbility in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743897&pid=S1409-4142200200030000600048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="49"></a><font face="Arial,Helvetica"><font size="-1"><b>49- </b>Hansson L, Lindholm LH, Ekbom T, Dahiof B, Lanke J, Schersten B, Wester P-O, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2-study. Lancet 1999; 354:1751-1756.</font></font> </p>     <p><a name="50"></a><font face="Arial,Helvetica"><font size="-1"><b>50- </b>Lewis EJ, Hunsicker LG, Ciarke WR, Beri T, Pohi MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.</font></font> </p>     <!-- ref --><p><a name="51"></a><font face="Arial,Helvetica"><font size="-1"><b>51- </b>Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001; 345: 861-869.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743900&pid=S1409-4142200200030000600051&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="52"></a><font face="Arial,Helvetica"><font size="-1"><b>52- </b>Dahlof B, Devereux RB, Kjeidsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743901&pid=S1409-4142200200030000600052&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="53"></a><font face="Arial,Helvetica"><font size="-1"><b>53- </b>Dahlof B, Devereux RV, Julius S, et al. Characteristics of 9.194 patients with left ventricular hypertrophy: the LIFE Study. Hypertension 1998; 32: 989-97</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743902&pid=S1409-4142200200030000600053&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="54"></a><font face="Arial,Helvetica"><font size="-1"><b>54- </b>Dahlof B, Devereux RB, de Faire U, et al The losartan lntervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. Am J Hypertens 1997; 10: 705-713.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743903&pid=S1409-4142200200030000600054&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="55"></a><font face="Arial,Helvetica"><font size="-1"><b>55- </b>Dahlof B, Keller SE, Makris L, Goldberg Al, Sweet CS, Limn NY. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-83</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743904&pid=S1409-4142200200030000600055&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="56"></a><font face="Arial,Helvetica"><font size="-1"><b>56- </b>Dahlof B, Lindhoim LH, Hansson L, Schersten B, Ekbom T, Wester PO Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743905&pid=S1409-4142200200030000600056&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="57"></a><font face="Arial,Helvetica"><font size="-1"><b>57-</b> Kjeldsen SE, Dahlof B, Devereux RB, Julius S et al for the LIFE Study Group. lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE Study. Am J Hypertens 2000; 13: 899-906.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743906&pid=S1409-4142200200030000600057&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="58"></a><font face="Arial,Helvetica"><font size="-1"><b>58- </b>Lindholm LH, lbsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortaity in diabetics patients of the LIFE study: a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743907&pid=S1409-4142200200030000600058&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="59"></a><font face="Arial,Helvetica"><font size="-1"><b>59- </b>Kjeldsen S, Dahlof B, Devereux R, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, lbsen H, Kristianson K et al for the LIFE study. Effects of losart&aacute;n on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losart&aacute;n lntervention For Endpoint Reduction (LIFE) Substudy. JAMA 2002; 288: 1491-1498</font></font> </p>     <!-- ref --><p><a name="60"></a><font face="Arial,Helvetica"><font size="-1"><b>60- </b>Devereux RB, Palmieri B, Liu J, Wachtell C, Bella J, Boman K, Gerdts E, Nieminen M, Papademetriou V and Dahlof B. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan lntervention For Endpoint Reduction study. J Hypertens 2002; 20: 1445-1450.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743909&pid=S1409-4142200200030000600060&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="61"></a><font face="Arial,Helvetica"><font size="-1"><b>61- </b>Dahiof B, Zanchetti A, Diez J, Nicholis MG, Yu CH-M, Barrios V, Aurup P, Smith R, Johansson M, for the REGAAL Study Investigators. Effects of losartan and atenolol on left ventricular mass and neurhormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-1864.</font></font> </p>     <!-- ref --><p><a name="62"></a><font face="Arial,Helvetica"><font size="-1"><b>62- </b>Wachtell K. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: LIFE Study. Circulation 2002; 106: 227-32.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743911&pid=S1409-4142200200030000600062&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="63"></a><font face="Arial,Helvetica"><font size="-1"><b>63- </b>Wachtell K. Change in diastolic left ventricular filling after one year of antihypertensive treatment: LIFE Study. Circulation 2002; 105: 1071-1076.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743912&pid=S1409-4142200200030000600063&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="64"></a><font face="Arial,Helvetica"><font size="-1"><b>64- </b>Gerdts E. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Study). Am J Cardiol 2002; 89: 399- 402.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743913&pid=S1409-4142200200030000600064&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="65"></a><font face="Arial,Helvetica"><font size="-1"><b>65- </b>Gerdts E. Correlates of left atrial size in hypertensive pat&iacute;ents with left ventricular hypertrophy: LIFE Study. Hypertension 2002; 39: 739-743</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743914&pid=S1409-4142200200030000600065&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="66"></a><font face="Arial,Helvetica"><font size="-1"><b>66- </b>Wachtell K. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. J Hypertens 2002; 20: 405-412.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743915&pid=S1409-4142200200030000600066&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="67"></a><font face="Arial,Helvetica"><font size="-1"><b>67- </b>Brunner HR, Gavras H. Angiotensin blockade for hypertension: a promise fulfilled. Lancet 2002; 359: 990-992.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743916&pid=S1409-4142200200030000600067&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="68"></a><font face="Arial,Helvetica"><font size="-1"><b>68- </b>Barrios V, Campuzano R, Pe&ntilde;a G, Guzm&aacute;n G, Ruilope LM. Estratificaci&oacute;n del riesgo cardiovascular en hipertensi&oacute;n en Atenci&oacute;n Primaria e impacto sobre el tratamiento antihipertensivo. Estudio DIORISC. Hipertensi&oacute;n 2002; 19: 114-120.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743917&pid=S1409-4142200200030000600068&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="69"></a><font face="Arial,Helvetica"><font size="-1"><b>69- </b>Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. lrbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743918&pid=S1409-4142200200030000600069&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><a name="70"></a><font face="Arial,Helvetica"><font size="-1"><b>70- </b>Hansson L, Lithell H, Skoog L, Baro F, B&aacute;nki CM, Breteler M et al. Study on Cognition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press 2000; 9: 146-151.</font></font> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743919&pid=S1409-4142200200030000600070&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a name="71"></a><font face="Arial,Helvetica"><font size="-1"><b>71- </b>Mann J, Julius 5, for the VALUE Trial Group. The Valsartan Antihypertensive long-term. Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7: 176-183.</font></font> </p>     <!-- ref --><p><a name="72"></a><font face="Arial,Helvetica"><font size="-1"><b>72- </b>Kjeldsen SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, Laraght J, Mc lnnes G, Smith B, Weber M, Zanchetti A. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Blood Press 2001; 10: 83-91.</font></font>    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=743921&pid=S1409-4142200200030000600072&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><br> &nbsp; </p>     <p><a name="*"></a><font face="Arial,Helvetica"><font size="-1"><a  href="#*a">*</a> Servicio de Cardiolog&iacute;a, Hospital Ram&oacute;n y Cajal, Madrid, Espa&ntilde;a.</font></font>     <br> <font face="Arial,Helvetica"><font size="-1"><a href="#*a">**</a> Unidad de Hipertensi&oacute;n. Hospital 12 de Octubre, Madrid, Espa&ntilde;a.</font></font>     <br> <font face="Arial,Helvetica"><font size="-1">Direcci&oacute;n para correspondencia:</font></font>     ]]></body>
<body><![CDATA[<br> <font face="Arial,Helvetica"><font size="-1">Ctra. de Colmenar, km 9.100. 28034 Madrid, Espa&ntilde;a.</font></font>     <br> <font face="Arial,Helvetica"><font size="-1">e-mail: <a  href="mailto:vbarriosa@meditex.es">vbarriosa@meditex.es</a></font></font> </p>      ]]></body>
<back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benegas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Artalejo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[De la Cruz Troca]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Guallar-Castilión]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Del Rey Calero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[La presión arterial en España. Distribución, grado de conocimiento, control y beneficios de una reducción en los niveles medios de presión arterial]]></article-title>
<source><![CDATA[Hipertensión]]></source>
<year>1999</year>
<volume>32</volume>
<page-range>908-1.002</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González Juanatey]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Alegria Ezquerra]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano Vidal]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[llisterri Caro]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[García Acuña]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[González Maqueda]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2001</year>
<volume>54</volume>
<page-range>139-149</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<collab>Ministerio de Sanidad y Consumo y Sociedad</collab>
<collab>Liga Española de Hipertensión arterial</collab>
<source><![CDATA[Consenso para el control de la presión arterial en España]]></source>
<year>1996</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<collab>Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure</collab>
<article-title xml:lang="en"><![CDATA[The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC-VI)]]></article-title>
<source><![CDATA[Arch lntern Med]]></source>
<year>1997</year>
<volume>157</volume>
<page-range>2313-2446</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<collab>Guidelines Subcommíttee</collab>
<article-title xml:lang="en"><![CDATA[Worid Health Organization lnternational Society of Hypertension guidelines for the management of hypertension]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>1999</year>
<month>19</month>
<day>99</day>
<volume>17</volume>
<page-range>151-183</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hipertension with left ventricular hypertrophy/diastolic dysfunction]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Sleight]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Opie]]></surname>
<given-names><![CDATA[FML]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinica cases in hypertension. Specific treatment strategies. II. Richmond upon Thames (Reino Unido)]]></source>
<year>2000</year>
<page-range>16-22</page-range><publisher-name><![CDATA[PAN Communications]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laragh]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Sealy]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Laragh]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<source><![CDATA[Hypertension: pathophysiology, diagnosis and management]]></source>
<year>1990</year>
<page-range>1329-1348</page-range><publisher-loc><![CDATA[Nueva York ]]></publisher-loc>
<publisher-name><![CDATA[Raven Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zitnay]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Siragy]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atheroscierosis]]></article-title>
<source><![CDATA[Miner Electrolyte Metab]]></source>
<year>1998</year>
<volume>24</volume>
<page-range>362-370</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermam]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Waih]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Sowers]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Angiotensin II biochemistryan physiologhy. Update on angiotensin II receptor blockers]]></article-title>
<source><![CDATA[Cardiovasc Rev]]></source>
<year>1997</year>
<volume>15</volume>
<page-range>75-100</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mac Mahon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rodgers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effects of blood pressure reduction in older patients: an overview of five randomised controlled trials in elderly hypertensives]]></article-title>
<source><![CDATA[Clin Exp Hypertens]]></source>
<year>1993</year>
<volume>15</volume>
<page-range>967-978</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mac Mahon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of ACE inhibitors, calcium antagonists and other blood-pressure-iowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure lowering Treatment Trialists Collaboration]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>356</volume>
<page-range>1955-1964</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maschio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Alberti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Janin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The angiotensinconverting-enzyme inhibition in progressive renal insufficiency Study Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1996</year>
<volume>334</volume>
<page-range>939-945</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moyé]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Basta]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cuddy]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effect of captopril of morbidity and mortality in patients with left ventricular dysfunction following myocardial infarction. Results of the Survival and Ventricular Enlargement (SAVE) trial]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1992</year>
<volume>327</volume>
<page-range>669-677</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<collab>The Heart Outcomes Prevention Evaluation study investigators</collab>
<article-title xml:lang="en"><![CDATA[Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>342</volume>
<page-range>145-153</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<collab>^dThe SOLVD lnvestigators</collab>
<article-title xml:lang="en"><![CDATA[Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1992</year>
<volume>327</volume>
<page-range>685-691</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hunsicker]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Bain]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Rohde]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1993</year>
<volume>329</volume>
<page-range>1456-1462</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<collab>PROGRESS Collaborative Group</collab>
<article-title xml:lang="en"><![CDATA[Randomised trial of a perindopril-based blood-pressure-iowering regimen among 6.105 individuas with previous stroke or transient ischaemic attack]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2001</year>
<volume>358</volume>
<page-range>1033-1041</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lindholm]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Niskanen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lanke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hedner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nikiason]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Luomanmaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dahloff]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Morlin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kariberg]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Wester]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Bjorck]]></surname>
<given-names><![CDATA[J-E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect angiotensin-convertingenzyme inhibition compared with convencional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>353</volume>
<page-range>611-616</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<collab>UK Prospective Diabetes Study Group</collab>
<article-title xml:lang="en"><![CDATA[Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1998</year>
<volume>317</volume>
<page-range>713-720</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lindhoim]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Ekbom]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dahloff]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[lanke]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Schersten]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wester]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Hedner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Randomised trial of old and new antihypertensive drugs in elderiy patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>354</volume>
<page-range>1751-1756</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Corazón e hipertensión]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[Nuevas fronteras en hipertensión]]></source>
<year>1998</year>
<volume>3</volume>
<page-range>29-63</page-range><publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Doyma]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pharmacologic treatment in hypertensive heart disease]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Di Marco]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiology]]></source>
<year>2001</year>
<page-range>8.1-8.8</page-range><publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Mosby]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[lsraili]]></surname>
<given-names><![CDATA[ZH]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cough and angioneurotic edema associated with angiotensin-converting-enzyme inhibitor therapy: a review of the literature and pathophysiology]]></article-title>
<source><![CDATA[Am Intern Med]]></source>
<year>1992</year>
<volume>117</volume>
<page-range>234-242</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bloom]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Continuation of initial antihypertensive medication after 1 year of therapy]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>1998</year>
<volume>20</volume>
<page-range>671-681</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conlin]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Gerth]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roehm]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Boccuzzi]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Four-year persistence patterns among patients initiating theraphy with the angiotensina II receptor antagonist losartán versus other antihypertensive drug classes]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2001</year>
<volume>23</volume>
<page-range>1999-2010</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paster]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Snavely]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Swett]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Draper]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[Al]]></given-names>
</name>
<name>
<surname><![CDATA[Soffer]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Swett]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting-enzyme inhibitors]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>1998</year>
<volume>20</volume>
<page-range>978-989</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Graff]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shute]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stoltz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ruff]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[levine]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Mallows]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Valsartan, a new angiotensin II antagonist of the treatment of essential hypertension. Efficacy, tolerability and safety compared to an angiotensin inhibitor. lisinopril]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>1997</year>
<volume>11</volume>
<page-range>483-489</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belcher]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hubner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Elmfeldt]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[lunde]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Candersartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>1997</year>
<volume>11</volume>
<page-range>585-589</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Esteras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Luque]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tamargo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Carrasco]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Herranz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro-Cid]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antihypertensive efficacy and tolerability of lercarnidipine in daily clinical practice. The ELYPSE study]]></article-title>
<source><![CDATA[Blood Pressure]]></source>
<year>2002</year>
<volume>11</volume>
<page-range>95-100</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sever]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Candersartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>1997</year>
<volume>11</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>591-595</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[Cl]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Angiotensin receptor antagonist: focus on losartan]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1995</year>
<volume>346</volume>
<page-range>1403-1407</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gillis]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Markham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[irbesartan: A review oí its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>1997</year>
<volume>54</volume>
<page-range>885-90</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Markham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Goa]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Valsartan: A review of its pharmacology and therapeutíc use in essential hypertension]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>1997</year>
<volume>54</volume>
<page-range>299-311</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Graff]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shute]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stoiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ruff]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[levine]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Mallows]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. Efficacy, tolerability and safety compared to an angiotensin- converting enzyme inhibitor, lisinopril]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>1997</year>
<volume>11</volume>
<page-range>483-489</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tikkanen]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Omvik]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>1995</year>
<volume>13</volume>
<page-range>1343-1351</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mimran]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Kerwin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nys]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Owens]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kassler-Taub]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Osbakken]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A randomised, double blind comparison of the angiotensin II receptor antagonist irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>1998</year>
<volume>12</volume>
<page-range>203-208</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kariberg]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Lins]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Hermansson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Efficacy and Safety of Teimisartan, a selectiva AT I receptor antagonist, compared with enalapril in ederly patients with Primary hypertension]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>1999</year>
<volume>17</volume>
<page-range>293-302</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Makris]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[Al]]></given-names>
</name>
<name>
<surname><![CDATA[Sweet]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Efficacy and tolerability of losartan potassium and atenolol in patients with mild or moderate essential hypertension]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>1995</year>
<volume>8</volume>
<page-range>578- 583</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corea]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoni]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Fogari]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[lnnocenti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Porcellati]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Providenza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meilenbrock]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bodin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. A comparative study of the efficacy and safety agonist amiodipine]]></article-title>
<source><![CDATA[Clin Pharm Ther]]></source>
<year>1996</year>
<volume>60</volume>
<page-range>341-346</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lombera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Soria]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Placer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Tomás]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión arterial]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2000</year>
<volume>53</volume>
<page-range>66-90</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang="en"><![CDATA[Diabetic nephropathy]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2002</year>
<volume>25</volume>
<page-range>S85-S89</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kassier-Taub]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Little]]></surname>
<given-names><![CDATA[John T]]></given-names>
</name>
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ruddy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[AdLer]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparative efficacy of two angiotensin II receptor antagonists, irbersartan and losartan, in mild to moderate hypertension]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>1998</year>
<volume>11</volume>
<page-range>445- 453</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersson]]></surname>
<given-names><![CDATA[OK]]></given-names>
</name>
<name>
<surname><![CDATA[Neldom]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The antihypertensive effect and tolerability of candersartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan]]></article-title>
<source><![CDATA[Blood Press]]></source>
<year>1998</year>
<volume>7</volume>
<page-range>53-59</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oparil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>2002</year>
<volume>16</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>17-23</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conlin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Spence]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Benedict]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bunt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Angiotensin II antagonist for hypertension: Are there differences in efficacy?]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>2000</year>
<volume>13</volume>
<page-range>418- 426</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lindhoim]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Niskanen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lanke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hedner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Niklason]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Luomanmaki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Morlin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kariberg]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Wester]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Bjorck]]></surname>
<given-names><![CDATA[J-E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect angiotensin-converting-enzyme inhibition compared with convencional therapy on cardiovascular morbidity and mortality in hypertension: Captopril Prevention Project (CAPPP) randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>353</volume>
<page-range>611-616</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Castaigne]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Leeuw]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mordidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the internacional Nifedipine GITS study: lntervention as a goal in hypertension Treatment (INSIGHT)]]></article-title>
<source><![CDATA[lancet]]></source>
<year>2000</year>
<volume>356</volume>
<page-range>366-372</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hedner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lund-Johansen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kjeidsen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lindhoim]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Syvertsen]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Lanke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Dahiof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kariberg]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Randomised trial of effects of calcium antagonists compared with diuretics and Beta-blockers on cardiocascular morbidity and morbility in hypertension: the Nordic Diltiazem (NORDIL) study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>356</volume>
<page-range>359-365</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lindholm]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Ekbom]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lanke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schersten]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wester]]></surname>
<given-names><![CDATA[P-O]]></given-names>
</name>
<name>
<surname><![CDATA[Hedner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2-study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>354</volume>
<page-range>1751-1756</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hunsicker]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Beri]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pohi]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Ritz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Atkins]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Rohde]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Raz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>851-860</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[de Zeeuw]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Keane]]></surname>
<given-names><![CDATA[WF]]></given-names>
</name>
<name>
<surname><![CDATA[Mitch]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Remuzzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Snapinn]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Shahinfar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy]]></article-title>
<source><![CDATA[N Eng J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>861-869</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Kjeidsen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>359</volume>
<page-range>995-1003</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[RV]]></given-names>
</name>
<name>
<surname><![CDATA[Julius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Characteristics of 9.194 patients with left ventricular hypertrophy: the LIFE Study]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>1998</year>
<volume>32</volume>
<page-range>989-97</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The losartan lntervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>1997</year>
<volume>10</volume>
<page-range>705-713</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Keller]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Makris]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[Al]]></given-names>
</name>
<name>
<surname><![CDATA[Sweet]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Limn]]></surname>
<given-names><![CDATA[NY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>1995</year>
<volume>8</volume>
<page-range>578-83</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lindhoim]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schersten]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ekbom]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wester]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1991</year>
<volume>338</volume>
<page-range>1281-1285</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kjeldsen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Julius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE Study]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>2000</year>
<volume>13</volume>
<page-range>899-906</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindholm]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[lbsen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Beevers]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cardiovascular morbidity and mortaity in diabetics patients of the LIFE study: a randomised trial against atenolol]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>359</volume>
<page-range>1004-1010</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kjeldsen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Julius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aurup]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Edelman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beevers]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[de Faire]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Fyhrquist]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[lbsen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kristianson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of losartán on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartán lntervention For Endpoint Reduction (LIFE) Substudy]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2002</year>
<volume>288</volume>
<page-range>1491-1498</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Palmieri]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wachtell]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bella]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Boman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gerdts]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nieminen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Papademetriou]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan lntervention For Endpoint Reduction study]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>1445-1450</page-range></nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Diez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholis]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[CH-M]]></given-names>
</name>
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Aurup]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of losartan and atenolol on left ventricular mass and neurhormonal profile in patients with essential hypertension and left ventricular hypertrophy]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>1855-1864</page-range></nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wachtell]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Change in systolic left ventricular performance after 3 years of antihypertensive treatment: LIFE Study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>106</volume>
<page-range>227-32</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wachtell]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Change in diastolic left ventricular filling after one year of antihypertensive treatment: LIFE Study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>105</volume>
<page-range>1071-1076</page-range></nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerdts]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Study)]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2002</year>
<volume>89</volume>
<page-range>399- 402</page-range></nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerdts]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Correlates of left atrial size in hypertensive patíents with left ventricular hypertrophy: LIFE Study]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>739-743</page-range></nlm-citation>
</ref>
<ref id="B66">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wachtell]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>405-412</page-range></nlm-citation>
</ref>
<ref id="B67">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brunner]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Gavras]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Angiotensin blockade for hypertension: a promise fulfilled]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>359</volume>
<page-range>990-992</page-range></nlm-citation>
</ref>
<ref id="B68">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Campuzano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Estratificación del riesgo cardiovascular en hipertensión en Atención Primaria e impacto sobre el tratamiento antihipertensivo. Estudio DIORISC]]></article-title>
<source><![CDATA[Hipertensión]]></source>
<year>2002</year>
<volume>19</volume>
<page-range>114-120</page-range></nlm-citation>
</ref>
<ref id="B69">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Lehnert]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brochner-Mortensen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gomis]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[lrbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>870-878</page-range></nlm-citation>
</ref>
<ref id="B70">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lithell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Skoog]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Baro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bánki]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Breteler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Study on Cognition and Prognosis in the Elderly (SCOPE): baseline characteristics]]></article-title>
<source><![CDATA[Blood Press]]></source>
<year>2000</year>
<volume>9</volume>
<page-range>146-151</page-range></nlm-citation>
</ref>
<ref id="B71">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Julius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Valsartan Antihypertensive long-term. Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design]]></article-title>
<source><![CDATA[Blood Press]]></source>
<year>1998</year>
<volume>7</volume>
<page-range>176-183</page-range></nlm-citation>
</ref>
<ref id="B72">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kjeldsen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Julius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brunner]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Henis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ekman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Laraght]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mc lnnes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation]]></article-title>
<source><![CDATA[Blood Press]]></source>
<year>2001</year>
<volume>10</volume>
<page-range>83-91</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
